A comprehensive analysis of Wnt/β-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer

Yan-Lei Lia, Yu-Fen Jin, Xiu-Xia Liu and Hong-Jun Li

Medical Examination Center, China-Japan Union Hospital of Jilin University, Changchun, China; Clinical Laboratory, The Second Hospital of Jilin University, Changchun, China

ABSTRACT

We aimed to investigate the effect of As2O3 treatment on Wnt/β-catenin signaling pathway-related genes and pathways in renal cancer. Illumina-based RNA-seq of 786-O cells with or without As2O3 treatment was performed, and differentially expressed genes (DEGs) were identified using Cuffdiff software. TargetMine was utilized to perform Gene Ontology (GO) pathway and Disease Ontology enrichment analyses. Furthermore, TRANSFAC database and LPIA method were applied to select differentially expressed transcription factors (TFs) and pathways related to Wnt/β-catenin signaling pathway, respectively. Additionally, transcriptional regulatory and pathway crosstalk networks were constructed. In total, 1684 DEGs and 69 TFs were screened out. The 821 up-regulated DEGs were mainly enriched in 67 pathways, 70 GO terms, and 46 disease pathways, while only 1 pathway and 5 GO terms were enriched for 863 down-regulated DEGs. A total of 18 DEGs (4 up-regulated and 14 down-regulated genes) were involved in the Wnt/β-catenin signaling pathway. Among the 18 DEGs, 4 ones were TFs. Furthermore, 211 pathways were predicted to be linked to the Wnt/β-catenin signaling pathway. In conclusion, As2O3 may have a significant effect on the Wnt/β-catenin signaling pathway for renal cancer treatment. The potential key DEGs are expected to be used as therapeutic targets.

ARTICLE HISTORY

Received 20 July 2017
Revised 21 November 2017
Accepted 6 March 2018

KEYWORDS

As2O3; renal cancer; differentially expressed gene; Wnt signaling pathway; therapeutic targets

Introduction

Renal cell carcinoma (RCC) is one of leading malignant condition in both males and females, with 62,700 estimated new cases and 14,240 estimated deaths in the United States in 2016 [1]. The treatment of RCC has been greatly improved over the past 15 years due to the advanced genomics and biological discoveries [2]. However, more effective forms of therapies are needed that will bring benefits for a higher percentage of patients.

Wnt family consists of 19 secreted ligands enriched by cysteine, which is essential for multiple developmental and physiological events, including proliferation, differentiation, migration, death, and polarity [3], and affects multiple intracellular signaling cascades, including the β-catenin-dependent and -independent pathways [4]. Furthermore, increasing evidences reveal that Wnt components are shared by other signaling pathways and crosstalk occurs between Wnt signaling with many other pathways, such as transforming growth factor β (TGF-β)-signaling pathway and fibroblast growth factor (FGF) pathways [5]. Notably, activated Wnt signaling pathway is frequently observed in early stages of many tumors, most tissues that normally depend on Wnt for repair or self-renewal [6]. Meanwhile, previous studies have demonstrated that multiple genes or proteins can affect the occurrence and development of renal cancer by targeting Wnt signaling pathway. For instance, Gnemmi et al. [7] have found that MUC1 drives epithelial–mesenchymal transition (EMT) in renal cancer through Wnt/β-catenin pathway. UBE3C promotes growth and metastasis of RCC via activating Wnt/β-Catenin pathway [8]. Besides, knock-down of MALAT1 reduces expression of proteins in Wnt/β-Catenin pathway in RCC cell lines [9]. RCC survival is suppressed in part due to inhibition of Wnt/β-catenin signaling by ethacrynic acid, ciclopirox olamine, and pir-octone olamine [10]. These studies suggest that the development of therapies targeting the Wnt signaling pathway may provide novel and effective treatment options for renal cancer patients.

CONTACT Hong-Jun Li hongjunli32@outlook.com Medical Examination Center, China-Japan Union Hospital of Jilin University, No.126 Xiantai Street, Changchun, 130033, China

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Arsenic trioxide (As$_2$O$_3$), as a traditional Chinese medicine, has been identified to play an important role in the research and treatment for cancers, such as acute breast cancer, acute promyelocytic leukemia, gastric cancer, neuroblastoma, and esophageal carcinoma [11]. It has reported that As$_2$O$_3$ induces apoptosis by reducing the activities of nuclear factor-kB (NF-kB) and human telomerase reverse transcriptase (hTERT) [12]. Recently, the role of As$_2$O$_3$ in renal cancer has also been reported, and As$_2$O$_3$ with amino acids can be used to treat renal cancer by down-regulating Bcl-2 and induce the apoptosis of renal cancer 786-O cells through up-regulating the expression of Bax [13]. However, the molecular mechanism of As$_2$O$_3$ treatment on renal cancer is still far from completely clear. Studies have shown that the Wnt signaling pathway plays critical roles in cell apoptosis, and some drugs or molecules affect apoptosis process in multiple cancers by targeting Wnt signaling pathway [14]. Therefore, we suspect that Wnt signaling pathway may play pivotal roles in the As$_2$O$_3$ treatment on renal cancer.

In order to certify our suspicion, the differentially expressed genes (DEGs) were screened after As$_2$O$_3$ treatment in 786-O renal carcinoma cell lines using bioinformatics methods. The Wnt signaling pathway-related genes, transcription factors (TFs), and crosstalk pathways were also explored in order to extend our understanding of the molecular mechanisms of As$_2$O$_3$ treatment on renal cancer and provide new insights for the further treatment of renal cancer.

Methods

Cell line and cell culture
Renal carcinoma cell line 786-O was purchased from the Cell Bank of Shanghai Institutes for Biological Sciences (Shanghai, China). The cell line was cultivated in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS, GIBCO BRL, Gaithersburg, MD), 100 IU/mL penicillin and 100 μg/mL streptomycin and cultured in a humidified 37°C incubator containing 5% CO$_2$.

Grouping and cell treatment
Two groups were set up for this study, namely control groups and As$_2$O$_3$ groups, with two samples for each group. According to the result of tetrazolium (MTT) assay, in which the 786-O cells were treated by different concentration of As$_2$O$_3$ (0, 0.5, 1, 2, 3, 5, 6 and 8 μmol/L), 2 μmol/L As$_2$O$_3$ was used to treat 786-O cells in As$_2$O$_3$ group due to higher cell viability. Thus, the cells in As$_2$O$_3$ group were exposure to 2 μmol/L As$_2$O$_3$ (Sigma, St Louis, MO) for 48 h. Equal volume of DMEM (GIBCO BRL, Gaithersburg, MD) was added to the control groups.

RNA isolation and sequencing
Total RNA of the four cell line samples were extracted using Trizol reagent (GIBCO BRL, Gaithersburg, MD) according to the manufacturer’s instructions, respectively. RNA sequencing was then performed using an Illumina HiSeq 2000 (Nanjing Vazyme Biotech Co., Ltd., Nanjing, China).

Quality control and mapping RNA-seq reads to reference genome
Fastx_toolkit (Version 0.0.13 from Assaf Gordon Hannon Lab) was utilized for quality control, and scoring systems of Sanger (Phred +33) was chosen for the read values. High-quality data were obtained from raw data by removing adapter and read values <10. Only the reads with length more than 50 after trimmed and the reads with more than 80% of high-quality (Q value ≥20) were selected. The TopHat2 software (http://ccb.jhu.edu/software/tophat/index.shtml) [15] was utilized to map the clean reads to the reference human genome (hg19) with mismatches ≤2. Genomics and refseq annotation files were obtained from the UCSC database (University of California Santa Cruz, http://genome.ucsc.edu/).

Identification of DEGs
The differential expression analysis of genes between As$_2$O$_3$ and control groups was performed by using Cuffdiff software (http://cufflinks.cbcb.umd.edu/manual.htm#cuffdiff) [16] with the cutoff criteria of p values <.05 and fold change >1.

Functional and pathway enrichment analyses
In order to obtain further insight into the involvement of DEGs in functional and metabolic pathways, the gene functional classification tool DAVID (Database for Annotation, Visualization and Integrated Discovery) (http://david.abcc.ncifcrf.gov/) [17] was used to perform Gene Ontology (GO) [including biological process (BP), cell component (CC), and molecular function (MF)] and KEGG pathway enrichment analyses. The p values were corrected for false discovery rate (FDR) by
Holm–Bonferroni [18,19], and FDR < .05 and count ≥ 2 were set as the cutoff criteria.

Construction of transcriptional regulatory networks

The differentially expressed TFs were identified from DEGs based on the TRANSFAC database (http://transfac.gbf.de/TRANSFAC/) [20]. Then target genes of Wnt/β-catenin signaling pathway-related TFs were predicted by UCSC database. Transcription regulatory networks were constructed based on the regulatory pairs and visualized by Cytoscape software (http://www.cytoscape.org/) [21].

Pathway-crosstalk analysis

Latent pathway identification analysis (LPIA) method proposed by Pham et al. [22] was used to analyze the crosstalk pathways related with Wnt/β-catenin signaling pathway. Afterwards, based on DEG annotation, the network composed of crosstalk pathways and related DEGs were visualized by Cytoscape software.

Results

Identification of DEGs and enrichment analyses

A total of 1684 DEGs between As2O3 treatment samples and controls were screened out, including 821 up-regulated genes and 863 down-regulated genes.

According to the GO functional enrichment analysis, the up-regulated genes (e.g., SMAD3 and FOSL1) were significantly enriched in a set of GO terms, such as programmed cell death and protein binding (Table 1). The down-regulated genes were markedly enriched in single-organism cellular process (e.g., TCF7L1 and FRAT1) and protein binding (e.g., NFATC3 and TCF7L1) (Table 2).

Furthermore, the pathway enrichment analysis showed that the up-regulated genes were distinctly enriched in multiple pathways, such as proteasome pathway (e.g., PSMA7, PSMB1, and PSMB3), MAPK signaling pathway (e.g., FOS and GADD45A), and p53 signaling pathway (e.g., CASP8 and CCND3). Meanwhile, the down-regulated genes were significantly enriched in Wnt signaling pathway (e.g., NFATC3 and TCF7L1), and the pathway of complement and coagulation cascades (e.g., CD55 and CFD) (Table 3).

Wnt signaling pathway analysis

According to Figure 1, four up-regulated genes [FOSL1 (FOS-like antigen 1), SMAD3 (SMAD family member 3), AXIN1 (axin 1), and CCND3 (cyclin D3)] and 14 down-regulated genes [e.g., NFATC3 (nuclear factor of activated T cells (NFAT), cytoplasmic 3), and TCF7L1 (TF 7-like 1)] participated in the Wnt signaling pathway.

Transcriptional regulatory network analysis

A total of 69 TFs were identified from the DEGs, including 32 up- and 37 down-regulated TFs. Furthermore, two up-regulated TFs (SMAD3 and FOSL1) and two down-regulated TFs (NFATC3 and TCF7L1) were involved in the Wnt signaling pathway. Additionally, there were 238 nodes (112 up- and 126 down-regulated DEGs) and 247 edges in the transcriptional regulatory network. Among the 238 DEGs, there were 27 TFs, and TCF7L1 was the hub, regulating a set of genes and other TFs (e.g., NFATC3 and SMAD3) (Figure 2).

Pathway-crosstalk analysis

In total, 211 pathways were predicted to be linked to Wnt signaling pathway. Among the pathways, the

| Table 1. The top 5 Gene Ontology terms with the lowest p values in BP, CC, and MF for the up-regulated differentially expressed genes. |
|--------------------|----------------|-------------------------------|--------------------------|
| Category | ID | Term | p value | Count | Genes |
| GO-BP | GO:0008150 | Biological process | 1.97E-37 | 651 | SMAD3, FOSL1, CCND3, DMA, LAMAI... |
| GO-BP | GO:0009967 | Cellular process | 1.76E-20 | 595 | SMAD3, FOSL1, CCND3, GPNPDA1, PARP2... |
| GO-BP | GO:0008152 | Metabolic process | 2.11E-20 | 510 | SMAD3, FOSL1, CCND3, MAFF, BRD1... |
| GO-BP | GO:0012501 | Programmed cell death | 2.36E-18 | 135 | SMAD3, FOSL1, CCND3, PARP2, ADAM8... |
| GO-BP | GO:0044327 | Cellular metabolic process | 3.96E-18 | 446 | SMAD3, FOSL1, MTO1, MCMB9, ARHI... |
| GO-CC | GO:0005622 | Intracellular | 1.09E-31 | 598 | SMAD3, FOSL1, CCND3, CDC137, FTF3... |
| GO-CC | GO:0044424 | Intracellular part | 1.00E-30 | 593 | SMAD3, FOSL1, CCND3, MAML1, ABCF2... |
| GO-CC | GO:0031974 | Membrane-enclosed lumen | 1.48E-22 | 255 | SMAD3, FOSL1, CENPE, POLR3C, RGS14... |
| GO-CC | GO:0043226 | Organelle | 1.87E-22 | 558 | SMAD3, FOSL1, CCND3, GPNPDA1, PARP2... |
| GO-CC | GO:0043233 | Organelle lumen | 2.35E-22 | 252 | SMAD3, FOSL1, POLR3C, RGS14, NUDC... |
| GO-MF | GO:0003674 | Molecular function | 7.56E-36 | 660 | SMAD3, FOSL1, CCND3, NFKB2, ATP1B3... |
| GO-MF | GO:0005488 | Binding | 3.16E-26 | 596 | SMAD3, FOSL1, CCND3, ATP1B3, NOTCH1... |
| GO-MF | GO:0005515 | Protein binding | 5.83E-18 | 470 | SMAD3, FOSL1, CCND3, ZNF593, NOSIP... |
| GO-MF | GO:1901363 | Heterocyclic compound binding | 4.16E-14 | 295 | SMAD3, FOSL1, UBE2T, SLC25A5, NGL2... |
| GO-MF | GO:0097159 | Organic cyclic compound binding | 6.91E-14 | 297 | SMAD3, FOSL1, CENPE, POLR3C, CAMKII... |

GO: Gene Ontology; BP: biological process; CC: cell component; MF: molecular function.
Table 2. The top 5 Gene Ontology terms with the lowest \( p \) values in BP, CC, and MF for the down-regulated differentially expressed genes.

| Category | ID     | Term                                | \( p \) value | Count | Genes                                                                 |
|----------|--------|-------------------------------------|----------------|-------|-----------------------------------------------------------------------|
| GO-BP    | GO:0008150 | Biological process                  | 1.22E-38       | 672   | TCF7L1, AKT3, HDAC6, FOXO6, BCL2L11, ...                             |
| GO-BP    | GO:0009987 | Cellular process                    | 1.62E-22       | 510   | TCF7L1, FRAT1, PARP3, CDH6, HMGB4, ...                               |
| GO-BP    | GO:004763 | Single-organism cellular process    | 1.40E-14       | 518   | TCF7L1, FRAT1, PARP3, CDH6, HMGB4, ...                               |
| GO-BP    | GO:004699 | Single-organism process             | 7.33E-14       | 555   | TCF7L1, FRAT1, PARP3, CDH6, HMGB4, ...                               |
| GO-BP    | GO:000152 | Metabolic process                   | 1.14E-10       | 492   | TCF7L1, NFRAT3, FOXO6, BCL2L11, FRAT1, ...                           |
| GO-CC    | GO:003575 | Cellular component                  | 3.95E-19       | 706   | TCF7L1, NFRAT3, FOXO6, BCL2L11, FRAT1, ...                           |
| GO-CC    | GO:0031988 | Membrane-bounded vesicle           | 1.77E-08       | 191   | CDH6, OPTN, CDH16, PDZK1P1, TNK2, ...                                |
| GO-CC    | GO:0031982 | Vesicle                             | 6.57E-08       | 193   | TNK2, INADL, CTDSP1, ATP8A1, IFIT3, ...                              |
| GO-CC    | GO:004421 | Extracellular region part           | 7.05E-08       | 198   | CDH16, PDZK1P1, INADL, CTDSP1, ATP8A1, ...                           |
| GO-CC    | GO:0098590 | Plasma membrane region             | 1.09E-07       | 45    | HDAC6, CDH16, INADL, EVC2, SCL44A3, ...                              |
| GO-MF    | GO:003674 | Molecular function                  | 1.49E-11       | 673   | TCF7L1, NFRAT3, CDH6, FOXO6, BCL2L11, FRAT1, ...                     |
| GO-MF    | GO:0005515 | Protein binding                     | 1.49E-11       | 455   | TCF7L1, NFRAT3, CDH6, FOXO6, BCL2L11, FRAT1, ...                     |
| GO-MF    | GO:0005515 | Protein binding                     | 1.49E-11       | 455   | TCF7L1, NFRAT3, CDH6, FOXO6, BCL2L11, FRAT1, ...                     |
| GO-MF    | GO:0043167 | Ion binding                         | 1.82E-05       | 267   | CDH16, CDH6, GPC6, SGK2, ARL4C, ...                                  |
| GO-MF    | GO:0046872 | Metal ion binding                   | 2.25E-05       | 191   | HDAC6, CDH6, CDH16, INADL, CTDSP1, ATP8A1, ...                      |

GO: Gene Ontology; BP: biological process; CC: cell component; MF: molecular function.

Table 3. The top 5 pathways with the lowest \( p \) values for the differentially expressed genes.

| Category | ID     | Term                                | \( p \) value | Count | Genes                                                                 |
|----------|--------|-------------------------------------|----------------|-------|-----------------------------------------------------------------------|
| Up-regulated genes | hsa03050 | Proteosome                          | 1.38E-10       | 11    | HSPA7, PSMB1, PSMB3, PSMB4, PSMB6, ...                                 |
|           | hsa04010 | MAPK signaling pathway              | 1.98E-07       | 19    | FOS, GADD45A, HRAS, MAP2K6, NFkB2, ...                                |
|           | hsa01100 | Metabolic pathways                  | 3.80E-07       | 18    | ATP5A1, ATP5B, CBS1, NDUFA1, POLD1, ...                               |
|           | hsa05145 | Toxoplasmosis                        | 2.73E-06       | 12    | CASC8, ITGA6, JAK2, LAMB3, MAP2K3, ...                               |
|           | hsa04115 | p53 signaling pathway               | 1.93E-05       | 8     | CASP8, CCND3, CEN1, G0S2, GADD45A, ...                               |
| Down-regulated genes | hsa04310 | Wnt signaling pathway               | 2.90E-52       | 14    | FOS, NFRAT3, AXIN2, TCF7L1, CUL4A, ...                               |
|           | hsa01100 | Metabolic pathways                  | 6.91E-10       | 52    | ALDH1A1, AXIN2, DCLK1, HOMER2, IMPA2, ...                             |
|           | hsa04610 | Complement and coagulation cascades  | 3.70E-08       | 11    | CD55, CD6, CFI, KLB1, SERPIN1A, ...                                  |
|           | hsa04146 | Peroxisome                          | 8.20E-05       | 8     | AXIN2, MTMR11, SOD3, SULCL2, TSPAN14, ...                            |
|           | hsa05150 | Staphylococcus aureus infection     | 4.25E-04       | 6     | C3, C4B, C5, CFD, CFI, FPR1, ...                                     |

Figure 1. The Wnt signaling pathway. Black blocks represent up-regulated genes, and gray blocks represent down-regulated genes.
The pathway of proteasome (hsa03050) was most closely linked to the Wnt signaling pathway (hsa04310) (Figure 3). A series of up-regulated genes were enriched in the proteasome pathway, such as PSMA7, PSMB1 and PSMB3. The up-regulated genes SMAD3 was enriched in multiple pathways, such as cell cycle (hsa04110), pathways in cancer (hsa05200), and adherens junction (hsa04520) (Table 4). Based on the DEG annotation, a set of DEGs were involved in the crosstalk of Wnt and other signaling pathways, such as TCF7L1, SMAD3 and FOSL1 (Figure 4).

Discussion

As$_2$O$_3$, as a treatment for cancers, has been studied for several decades. However, the molecular mechanisms of As$_2$O$_3$ treatment in renal cancer remains not clear, especially the effect of As$_2$O$_3$ on the Wnt signaling
pathway. In this study, 1684 DEGs between As2O3 treatment samples and controls were identified, including 821 up- and 863 down-regulated genes. Among those DEGs, SMAD3, FOSL1, NFATC3 and TCF7L1 were identified as TFs and predicted to be associated with the Wnt signaling pathway.

**SMAD3** encodes a member of the smad family. SMAD proteins are signal transducers and transcriptional modulators that are activated by TGF-β and mediate multiple signaling pathways [23]. Crosstalk between Smad and Wnt signaling has been reported in several kinds of cancer, such as pancreatic ductal adenocarcinoma and hepatocellular carcinoma [24], as well as kidney fibrosis [25]. In this study, according to the results of enrichment analyses, SMAD3 was enriched in the functions of cell death and apoptotic process and a set of Disease Ontology terms about cancer. TGF-β acts as a tumor suppressor during the early stages of tumorigenesis, and the ability of TGF-β/SMAD3 signal in tumor suppression has been demonstrated by multiple studies [26–28]. A recent study has demonstrated that nuclear expression of Smad3 is closely related to prognosis of clear cell RCC patients [29]. Taken together, As2O3 may play an anti-apoptosis role in renal cancer by up-regulating the expression of SMAD3 as well as the pathway crosstalk between TGF-β/SMAD3 and Wnt signaling pathway.

**FOSL1** encodes fos-like antigen 1, also known as *Fra1*, a member of Fos gene family, which regulates cell proliferation, differentiation, and transformation [30]. **FOSL1** can function as either an activator or a repressor to control the equilibrium between migration and adhesion in sprouting angiogenesis, which is critical in tumorigenesis [31,32]. In this study, **FOSL1** was up-regulated in the 786-O cells with As2O3 treatment, while a study has reported that Fosl1 induces transformation and invasiveness of human epithelial adenocarcinoma cells [33], which is inconsistent with the result of this study. It may be due to that during the early stage of As2O3 treatment, the expression of **FOSL1** is not

---

**Figure 3.** The pathway crosstalk between Wnt signaling pathway and other pathways (top 10 at weight scores). The thickness of the edges is directly proportional to the significance of interaction between any two pathways.

**Table 4.** The differentially expressed genes enriched in the crosstalk pathways of the Wnt signaling pathway.

| Pathway                   | Differentially expressed genes                                                                 |
|---------------------------|-------------------------------------------------------------------------------------------------|
| hsa04110                  | CCND3*, CCNE1*, CDCA5A*, E2F4*, GADD45A*, MERTK*, RALBP1*, RRP9*, SART1*, SMAD3*               |
| hsa05200                  | BRAF*, BRPF1*, CASP8*, CCNE1*, FOS*, HRAS*, HSP90AA1*, IKBKB*, ITGA6*, LAMB3*, MTO1*, NFKB2*, PDGFRB*, RRP9*, SERGFR*, SMAD3*, WRN* |
| hsa05220                  | BRAF*, HRAS*, IKBKB*, SMAD3*                                                                   |
| hsa00860                  | ALAS1*, BLVBR*, HAXO1*, HHRL2, INO80, UGT1A6                                                  |
| hsa03050                  | PSMA7*, PSMB1*, PSMB3*, PSMB4*, PSMB6*, PSMC3*, PSMC4*, PSMD1*, PSMD3*, PSMD7*                |
| hsa04310                  | FRAT1, CAMK2G, MMP7, WNT5B, WNT10B, NFATC3, AXIN2, TCF7L1, PRICKLE2, CAMK2D, SFRP2, NDK2, DAAM2, CUL1 |
| hsa04350                  | E2F4*, INHBB*, PPP2CB*, SMAD1*, SMAD3*                                                      |
| hsa05142                  | CASP8*, FOS*, IFNGR2*, IKBKB*, MAPK13*, PHLPP1*, PPP2CB*, SMAD3*                             |
| hsa04520                  | FER*, PTPN6*, PVRIL1*, RPS6KA4*, SMAD3*                                                      |
| hsa05210                  | BRAF*, FOS*, SMAD3*                                                                           |
| Hsa05212                  | BRAF*, IKBKB*, SMAD3*, E2F2, E2F3, RAD51                                                      |

*Up-regulated genes.
effectively influenced, and with the prolonged time of As$_2$O$_3$ treatment, the expression of FOSL1 may be decreased, which is needed to be further investigated.

NFATC3 encodes a member of the nuclear factors of activated T cells DNA-binding transcription complex, and it is important for T-cell development and essential for cancer chemoresistance [34]. NFAT proteins are able to inhibit the Wnt/β-catenin pathway via participating in regulating cell proliferation and differentiation [35,36]. Study has reported that NFAT signaling controls nephron formation, and NFATC3 is abundantly expressed in the metanephric mesenchyme [37]. In de novo renal allograft recipients, expression levels of NFAT-regulated genes are closely related to the clinical outcomes [38]. Furthermore, NFAT has been recently demonstrated to play pivotal roles in kidney ischemia/reperfusion (I/R) injury [39]. There is no evidence to support the association of NFATC3 with renal cancer so far, while the increased NFATC3 expression has been detected in human angiosarcoma that was induced by secreted frizzled-related protein 2 (SFRP2) [40]. Collectively, As$_2$O$_3$ treatment may affect the Wnt/β-catenin pathway through decreasing the expression of NFATC3 in renal cancer.

TCF7L1 (also known as TCF3) encodes a member of the T-cell factor/lymphoid enhancer factor family of TFs, which are activated by β-catenin and mediate the Wnt signaling pathway [41]. A previous study has demonstrated that the expression of TCF1 that is the homolog of TCF7L1 is significantly higher in clear cell RCC than in normal tissue [42]. Besides, in the transcriptional regulatory network, TCF7L1 regulated other TFs, such as SMAD3 and NFATC3. Taken together, the Wnt signaling pathway may be affected by As$_2$O$_3$ in renal cancer via the reduced expression of TCF7L1.

Furthermore, in this study, the pathway of proteasome (hsa03050) was most closely related to the Wnt signaling pathway, and the proteasome pathway was significantly enriched by a set of up-regulated DEGs that encode subunits of proteasome, such as PSMA7 and PSMB1. Proteasomes, along with ubiquitin (Ub), are essential components of the energy-dependent, nonlysosomal proteolytic pathway. β-catenin in the Wnt signaling pathway exerts functions in cells depending on the proteasome [43]. The levels of mRNAs for the subunits of proteasomes are high in rapidly proliferating renal cancer cells [44]. Besides, study has reported that PSMB1 is highly expressed in RCCs, comparing with the
normal kidney tissues [45]. Therefore, the Wnt signaling pathway may be influenced by As2O3 in renal cancer through the proteasome pathway.

Despite the aforementioned results, there were still some limitations in this study. The predicted results, such as expression of the discussed genes, and the associations between genes and Wnt signaling pathway, were required to be confirmed by experiments in renal cancer tissues, which would be conducted in our future study and reported separately.

Conclusions

In conclusion, 1684 DEGs (821 up- and 863 down-regulated genes) between As2O3 treatment samples and controls were identified. Among them, SMAD3, FOSL1, NFATC3 and TCF7L1 were identified as TFs and predicted to be correlated with the Wnt signaling pathway. Furthermore, the pathway of proteasome was most closely linked to the Wnt signaling pathway. These genes and pathways may play pivotal roles in the As2O3 treatment of renal cancer. These findings may provide new information for the molecular mechanisms of As2O3 treatment on renal cancer, especially the influence of As2O3 on the Wnt signaling pathway in renal cancer.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
[2] Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2013;349:g94797.
[3] Kikuchi A, Yamamoto H, Sato A, Matsumoto S. New insights into the mechanism of Wnt signaling pathway activation. Int Rev Cell Mol Biol. 2011;291:e71.
[4] Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Rev Dev Biol. 2004;20:781–810.
[5] Chaudhary M, Direnzo D, Shi XD, et al. TGF-β3Smad3 promotes smooth muscle cell de-differentiation and proliferation through crosstalk with the Wnt/β-catenin pathway. Arterioscler Thromb Vasc Biol. 2015;35: A227–A227.
[6] Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149:1192–1205.
[7] Gnemmi V, Boulleaz A, Gaudelot K, et al. MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/β-catenin pathway and interaction with SNAIL promoter. Cancer Lett. 2014;346:225–236.
[8] Wen JL, Wen XF, Li RB, et al. UBE3C promotes growth and metastasis of renal cell carcinoma via activating Wnt/β-catenin pathway. PLoS One. 2015;10:e0115622.
[9] Hirata H, Hinoda Y, Shahryari V, et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through EzH2 and interacts with miR-205. Cancer Res. 2015;75:1322–1331.
[10] Schulz-Hausmann SA, Schmeel LC, Schmeel FC, et al. Targeting the Wnt/beta-catenin pathway in renal cell carcinoma. Anticancer Res. 2014;34:4101–4108.
[11] Chow SK, Chan JY, Fung KP. Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J Cell Biochem. 2004;93:173–187.
[12] Xu W, Wang Y, Tong H, et al. Downregulation of hTERT: an important As2O3 induced mechanism of apoptosis in myelodysplastic syndrome. PLoS One. 2014;9:e113199.
[13] Wei Y, Changfu L, Yongsheng C, et al. Arsenic trioxide combined with ascorbic acid inhibit human renal clear cell carcinoma 786-O cell proliferation and bcl-2, bax protein expression. J Modern Oncol. 2014;3:519–522.
[14] Suh Y, Afaq F, Johnson JJ, et al. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways. Carcinogenesis. 2009;30:300–307.
[15] Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25:1105–1111.
[16] Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511–515.
[17] Da Wei Huang BTS, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2008;4:44–57.
[18] Shaffer JP. Multiple hypothesis testing. Annu Rev Psychol. 1995;46:561–584.
[19] Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65–70.
[20] Wingender E. The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation. Brief Bioinform. 2008;9:326–332.
[21] Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13: 2498–2504.
[22] Pham L, Christodoulou K, Schaus S, et al. Network-based prediction for sources of transcriptional dysregulation using latent pathway identification analysis. Proc Natl Acad Sci USA. 2011;108:13347–13352.
[23] Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature. 1998;394:909–913.
[24] Zhang H, Liu C, Kong Y, et al. TGFβ signaling in pancreatic ductal adenocarcinoma. Tumor Biol. 2015;36:1613–1618.
[25] Fan Y, Wang N, Chuang P, et al. Role of HIPK2 in kidney fibrosis. Kidney Int. 2014;84:97–101.
[26] Bae E, Ooshima A, Kim S-J. Distinctive roles of Smad3 C-tail and linker phosphorylation between cancer
progression and suppression in TGF-beta1/Smad3 signal. Cancer Res. 2014;74:1043.

[27] Singha P, Pandeswara S, Venkatchalam M, et al. Interplay of Smad2 and Smad3 during TGF-β induced TMEPAI/PMEPA1 mediated triple negative breast cancer cell growth. Cancer Res. 2016;76:P2-06-08.

[28] Chen H-S, Bai M-H, Zhang T, et al. Ellagic acid induces cell cycle arrest and apoptosis through TGF-β/Smad3 signaling pathway in human breast cancer MCF-7 cells. Int J Oncol. 2015;46:1730–1738.

[29] Park JH, Lee C, Suh JH, et al. Nuclear expression of Smad proteins and its prognostic significance in clear cell renal cell carcinoma. Hum Pathol. 2013;44:2047–2054.

[30] Matsui M, Tokuhara M, Konuma Y, et al. Isolation of human fos-related genes and their expression during monocyte-macrophage differentiation. Oncogene. 1990;5:249–255.

[31] Galvagni F, Orlandini M, Oliviero S. Role of the AP-1 transcription factor FOSL1 in endothelial cells adhesion and migration. Cell Adh Migr. 2013;7:408–411.

[32] Mansfield AS, Markovic SN. Inhibition of angiogenesis for the treatment of metastatic melanoma. Curr Oncol Rep. 2013;15:492–499.

[33] Kustikova O, Kramerov D, Grigorian M, et al. Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol. 1998;18:7095–7105.

[34] He DX, Gu XT, Jiang L, et al. A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer. Mol Pharmacol. 2014;86:536–547.

[35] Huang T, Xie Z, Wang J, et al. Nuclear factor of activated T cells (NFAT) proteins repress canonical Wnt signaling via its interaction with Dishevelled (Dvl) protein and participate in regulating neural progenitor cell proliferation and differentiation. J Biol Chem. 2011;286:37399–37405.

[36] Wang Q, Zhou Y, Rychahou P, et al. NFAT5 represses canonical Wnt signaling via inhibition of β-catenin acetylation and participates in regulating intestinal cell differentiation. Cell Death Dis. 2013;4:e671.

[37] Burn S, Webb A, Berry R, et al. Calcium/NFAT signaling promotes early nephrogenesis. Dev Biol. 2011;352:288–298.

[38] Sommerer C, Zeier M, Meuer S, et al. Monitoring of calcineurin inhibitors by NFAT regulated gene expression in de novo renal allograft recipients on cyclosporine A. Clin Nephrol. 2015;84:165–172.

[39] Zhang Z-Y, Wu Y-Q, Luo H, et al. The effect of nuclear factor of activated T-cells (NFAT) in kidney I/R mediated by C5a/C5aR. Int J Clin Exp Med. 2015;8:15535.

[40] Courtwright A, Siamakpour-Reihani S, Arbiser JL, et al. Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway. Cancer Res. 2009;69:4621–4628.

[41] Shy BR, Wu CI, Khramtsova GF, et al. Regulation of Tcf7l1 DNA binding and protein stability as principal mechanisms of Wnt/β-catenin signaling. Cell Rep. 2013;4:1–9.

[42] Nikuševa-Martić T, Šerman L, Zeljko M, et al. Expression of secreted frizzled-related protein 1 and 3, T-cell factor 1 and lymphoid enhancer factor 1 in clear cell renal cell carcinoma. Pathol Oncol Res. 2013;19:545–551.

[43] Zeng L, Fagotto F, Zhang T, et al. The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell. 1997;90:181–192.

[44] Kanayama H-o, Tanaka K, Aki M, et al. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res. 1991;51:6677–6685.

[45] Weinzierl AO, Lemmel C, Schoor O, et al. Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics. 2007;6:102–113.